<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00289445</url>
  </required_header>
  <id_info>
    <org_study_id>jth_003</org_study_id>
    <nct_id>NCT00289445</nct_id>
  </id_info>
  <brief_title>Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (&gt;= Second-line Treatment)</brief_title>
  <official_title>Open, Multi-center Phase I/II Trial With Mitomycin C in Combination With 5-Fluorouracil and Folinic Acid in Pretreated Patients With Metastatic Gastrointestinal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The aim of this study was to define the maximum tolerated dose (MTD) of bolus mitomycin C&#xD;
      (MMC) in combination with 24 h-continuous infusion of 5-fluorouracil (FU) plus folinic acid,&#xD;
      and to assess the toxicity and activity in patients with previously treated colorectal and&#xD;
      gastric cancer. Escalating doses of MMC starting from 6 mg m(-2) in 2 mg m(-2)-steps to a&#xD;
      maximum of 10 mg m(-2) were applied on days 1 and 22, given to fixed doses of 5-FU (2.600 mg&#xD;
      m(-2)) as 24 h infusion and folinic acid 500 mg m(-2) prior to 5-FU weekly for 6 weeks&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <completion_date>March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose (MTD) of bolus mitomycin C (MMC) in combination with 24 h-continuous infusion of 5-fluorouracil (FU) plus folinic acid</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>activity</measure>
  </primary_outcome>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Phase 1 (dose escalation)&#xD;
&#xD;
          -  patients with histological proven gastrointestinal neoplasms, without standard therapy&#xD;
             option&#xD;
&#xD;
          -  measurable or evaluable disease&#xD;
&#xD;
          -  &gt;= second-line therapy (metastasized stage) Phase 2 (efficacy)&#xD;
&#xD;
          -  patients with proven colorectal neoplasms&#xD;
&#xD;
          -  measurable disease, metastasized&#xD;
&#xD;
          -  previous chemotherapy with 5-FU/FA (&quot;AIO-regimen&quot;)&#xD;
&#xD;
          -  age between 18 and 75 years, both male and female&#xD;
&#xD;
          -  life expectancy &gt; 3 months&#xD;
&#xD;
          -  WHO-performance status &lt;= 2&#xD;
&#xD;
          -  adequate bone marrow function: hemoglobin &gt;= 10 mg/dl, neutrophils &gt;= 2.0 *&#xD;
             1000000000/l, thrombocytes &gt;= 150 * 1000000000/l&#xD;
&#xD;
          -  adequate renal and liver function: bilirubin &lt;= 1.25 * ULN(&lt;= 1.5 ULN * by liver&#xD;
             metastases), creatinine &lt;= 1.25 * ULN, ASAT and ALAT &lt;= 3 * ULN (&lt;= 5* ULN by liver&#xD;
             metastases; AP &lt;= 3* ULN&#xD;
&#xD;
          -  written informed consent prior to inclusion into the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pretreated with mitomycin c&#xD;
&#xD;
          -  contraindication concerning 5-FU (e.g. anxiety, myocardial infarction within last 6&#xD;
             months, significant toxicities during previous therapy with 5-FU&#xD;
&#xD;
          -  florid infections&#xD;
&#xD;
          -  ileus or subileus, morbus crohn or colitis, ulcerative&#xD;
&#xD;
          -  actual chronic diarrhea&#xD;
&#xD;
          -  other uncontrolled severe concurrent disease excluding cytotoxic intervention&#xD;
&#xD;
          -  second malignancy except basal cell carcinoma or cervical carcinoma in situ&#xD;
&#xD;
          -  known cns metastases or carcinomatous leptomeningitis&#xD;
&#xD;
          -  pregnancy or lactation period&#xD;
&#xD;
          -  no effective contraception&#xD;
&#xD;
          -  concomitant treatment with another antineoplastic agents&#xD;
&#xD;
          -  participation in another clinical trial within the last 4 weeks&#xD;
&#xD;
          -  patients being unwilling or unable to undergo trial specific procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten Bokemeyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen (PI until 30Nov2004)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joerg T Hartmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>February 8, 2006</study_first_submitted>
  <study_first_submitted_qc>February 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2006</study_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

